1007877-57-7

Basic information

• Product Name: (S)-Tert-butyl (4-amino-1-phenylbutan-2-yl)carbamate
• CAS NO: 1007877-57-7
• Molecular Formula: C₁₅H₂₄N₂O₂
• Molecular Weight: 264.368
• Mol File: 1007877-57-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (S)-Tert-butyl (4-amino-1-phenylbutan-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Tert-butyl (4-amino-1-phenylbutan-2-yl)carbamate(1007877-57-7)
• EPA Substance Registry System: (S)-Tert-butyl (4-amino-1-phenylbutan-2-yl)carbamate(1007877-57-7)

Safety Data

• Hazardous Substances Data: 1007877-57-7(Hazardous Substances Data)

Usage

Description

(S)-Tert-butyl (4-amino-1-phenylbutan-2-yl)carbamate is a carbamate derivative chemical compound, commonly utilized as an intermediate in the pharmaceutical industry for research and drug development. It has a molecular formula of C16H25N3O2, a molecular weight of 291.39 g/mol, and appears as a white to off-white solid. (S)-Tert-butyl (4-amino-1-phenylbutan-2-yl)carbamate is soluble in common organic solvents but sensitive to moisture, necessitating proper storage and handling precautions.

Uses

Used in Pharmaceutical Research and Drug Development:
(S)-Tert-butyl (4-amino-1-phenylbutan-2-yl)carbamate is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique chemical structure allows it to be a versatile building block in the creation of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic chemistry, (S)-Tert-butyl (4-amino-1-phenylbutan-2-yl)carbamate serves as a valuable compound for the synthesis of complex organic molecules. Its reactivity and functional groups make it a useful component in the development of novel chemical entities with potential applications in various industries.
Used in Chemical Manufacturing:
(S)-Tert-butyl (4-amino-1-phenylbutan-2-yl)carbamate is also employed in the chemical manufacturing industry as a key component in the production of specialty chemicals and materials. Its properties and reactivity contribute to the development of innovative products with specific applications in various markets.

Upstream product

• 3182-95-4 L-Phenylalaninol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 126301-19-7 (2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropyl methanesulfonate 
• 66605-57-0 (S)-N-tert-butoxycarbonyl-2-amino-3-phenylpropanol 
• 172695-25-9 (S)-3-<(tert-butoxycarbonyl)amino>-4-phenylbutanenitrile 

Downstream Products

• 1007875-27-5 C₂₇H₃₆N₂O₅S 
• 1007877-58-8 C₁₉H₃₂N₂O₂ 

Relevant articles and documents

Development of Chiral Organosuperbase Catalysts Consisting of Two Different Organobase Functionalities

In the field of chiral Br?nsted base catalysis, a new generation of chiral catalysts has been highly anticipated to overcome the intrinsic limitation of pronucleophiles that are applicable to the enantioselective reactions. Herein, we reveal conceptually new chiral Br?nsted base catalysts consisting of two different organobase functionalities, one of which functions as an organosuperbase and the other as the substrate recognition site. Their prominent activity, which stems from the distinctive cooperative function by the two organobases in a single catalyst molecule, was demonstrated in the unprecedented enantioselective direct Mannich-type reaction of α-phenylthioacetate as a less acidic pronucleophile. The present achievement would provide a new guiding principle for the design and development of chiral Br?nsted base catalysts and significantly broaden the utility of Br?nsted base catalysis in asymmetric organic synthesis.

Entropy-controlled catalytic asymmetric 1,4-type Friedel-crafts reaction of phenols using conformationally flexible guanidine/bisthiourea organocatalyst

Soft and weak cooperation: Conformationally flexible organic compounds were found to promote the title transformation. These "soft" organocatalysts, which are able to control processes through the differential activation entropies (ΔΔS*S-R) of

COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters